Form 8-K - Current report:
SEC Accession No. 0000950170-24-096139
Filing Date
2024-08-13
Accepted
2024-08-13 16:02:45
Documents
13
Period of Report
2024-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atyr-20240813.htm   iXBRL 8-K 49403
2 EX-99.1 atyr-ex99_1.htm EX-99.1 156396
3 GRAPHIC img137952089_0.jpg GRAPHIC 10984
  Complete submission text file 0000950170-24-096139.txt   348151

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atyr-20240813.xsd EX-101.SCH 26205
15 EXTRACTED XBRL INSTANCE DOCUMENT atyr-20240813_htm.xml XML 4710
Mailing Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121
Business Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121 8587318389
aTYR PHARMA INC (Filer) CIK: 0001339970 (see all company filings)

EIN.: 203435077 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37378 | Film No.: 241201266
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)